GLP-1 analogs have been at the forefront of therapy for Type 2 Diabetes in humans, due to their observed incretin effect: augmentation of glucose-dependent insulin secretion in the postprandial period [9]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.